Composition of antibody-drug conjugate
An antibody-drug conjugate (ADC) is a type of biopharmaceutical drug that is composed of an antibody and a cytotoxic drug. The purpose of an ADC
An antibody-drug conjugate (ADC) is a type of biopharmaceutical drug that is composed of an antibody and a cytotoxic drug. The purpose of an ADC
ADC, or antibody-drug conjugate, is a type of drug that combPrinciple ofines an antibody with a toxic drug in order to specifically target and kill
Recently, Pfizer of the United States and its German partner BioNTech countersued rival Moderna for the patent of the COVID-19 vaccine technology. broad” and “unenforceable”.
On November 30, 2022, Ferring Pharmaceuticals announced that its microbiome therapy REBYOTA® (RBX2660) was approved by the FDA, becoming the first approved fecal microbial therapy.
In recent years, chimeric antigen receptor (CAR) T-cell therapy for hematological malignancies has become a major breakthrough in cell therapy. To date, the U.S. Food
Antibody-drug conjugates (ADCs) have achieved remarkable efficacy in cancer treatment and have attracted worldwide attention. Although ADCs pose significant challenges to researchers, especially in identifying
The transcription factor family consists of c-MYC, L-MYC and N-MYC, which are the main regulators of cellular processes such as cell proliferation, cell differentiation, cell
Protein-polymer conjugates are widely used as disease therapeutics and have advantages such as high target specificity. but their use also faces some challenges: rapid clearance
We are not unfamiliar with vaccines, but few people know about vaccine adjuvants. The so-called adjuvant refers to the substance added to the vaccine that
Antibody-dependent cell-mediated cytotoxicity (ADCC) is a potent mechanism of cytotoxicity, mainly mediated by natural killer (NK) cells. When specific antibodies bind to the targeted cell
Tumor markers (TM) refer to the synthesis and secretion of tumor cells and gene expression during the occurrence and proliferation of malignant tumors, or the
On November 10, when AstraZeneca announced its third-quarter 2022 results, it also announced that it would not submit a listing application for the new crown